Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients

Next Previous
Trial Profile

Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions

Most Recent Events

  • 01 Aug 2022 Results of an analysis assessed co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel published in the Breast Cancer Research and Treatment
  • 01 May 2017 Status changed from active, no longer recruiting to completed.
  • 24 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top